{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:52:18Z","timestamp":1783651938988,"version":"3.55.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1053\/j.seminhematol.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T17:52:51Z","timestamp":1704477171000},"page":"119-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies"],"prefix":"10.1053","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-1634","authenticated-orcid":false,"given":"Azra","family":"Borogovac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.001_bib0001","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0002","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"10396","key":"10.1053\/j.seminhematol.2024.01.001_bib0003","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.01.001_bib0004","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1053\/j.seminhematol.2024.01.001_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.01.001_bib0007","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0008","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1053\/j.seminhematol.2024.01.001_bib0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.01.001_bib0010","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.001_bib0011","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.001_bib0012","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.001_bib0013","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.01.001_bib0014","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.01.001_bib0016","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.001_bib0017","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.001_bib0018","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.01.001_bib0019","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2017-01-761973","article-title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","volume":"129","author":"Fischer","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.001_bib0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"7897","key":"10.1053\/j.seminhematol.2024.01.001_bib0021","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0022","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cpim.108","article-title":"Purification, culture, and CD19-CAR lentiviral transduction of adult and umbilical cord blood NK cells","volume":"131","author":"Herrera","year":"2020","journal-title":"Curr Protoc Immunol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.001_bib0023","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/eji.1830230705","article-title":"New simplified molecular design for functional T cell receptor","volume":"23","author":"Brocker","year":"1993","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0024","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.001_bib0026","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.001_bib0027","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.001_bib0028","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered cytokine signaling to improve CAR T cell effector function","volume":"12","author":"Bell","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.001_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J Exp Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.001_bib0031","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/leu.2014.215","article-title":"IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia","volume":"29","author":"Pegram","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.001_bib0032","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.001_bib0033","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","article-title":"Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center","volume":"57","author":"Borogovac","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.01.001_bib0034","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2011-02-337691","article-title":"DARTs take aim at BiTEs","volume":"117","author":"Rader","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.01.001_bib0035","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0036","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11899-011-0106-x","article-title":"Immune reconstitution in chronic lymphocytic leukemia","volume":"7","author":"Riches","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.01.001_bib0037","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2174\/138161212801227023","article-title":"Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy","volume":"18","author":"Riches","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.001_bib0038","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion'","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0039","first-page":"157","article-title":"Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type","volume":"49","author":"Herrmann","year":"1982","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.001_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0145-2126(97)00152-5","article-title":"Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment","volume":"22","author":"Van den Hove","year":"1998","journal-title":"Leuk Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.001_bib0041","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D'Arena","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.001_bib0042","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2567.2010.03308.x","article-title":"T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies","volume":"131","author":"Lindqvist","year":"2010","journal-title":"Immunology"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.001_bib0043","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.001_bib0044","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.001_bib0045","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0046","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0047","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.001_bib0048","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.001_bib0049","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOH.0000000000000559","article-title":"Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies","volume":"27","author":"Sterner","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0051","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.001_bib0052","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0053","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.01.001_bib0054","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.001_bib0055","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"303","key":"10.1053\/j.seminhematol.2024.01.001_bib0056","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.001_bib0057","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.001_bib0058","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0059","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/10428194.2018.1461862","article-title":"Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome","volume":"60","author":"Alderuccio","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2019-000218","article-title":"CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells","volume":"8","author":"Martens","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0061","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.001_bib0062","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.01.001_bib0063","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.001_bib0064","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1189\/jlb.5RU0817-315R","article-title":"Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy","volume":"102","author":"Wang","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.001_bib0065","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0066","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0067","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.001_bib0068","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.13562","article-title":"Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells","volume":"171","author":"Evans","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0069","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hon.3036","article-title":"Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies","volume":"40","author":"Yang","year":"2022","journal-title":"Hematol Oncol"},{"issue":"7750","key":"10.1053\/j.seminhematol.2024.01.001_bib0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.001_bib0071","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.001_bib0072","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.001_bib0073","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/RLU.0000000000003756","article-title":"Prognostic impact of 18F-FDG PET\/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells","volume":"46","author":"Sesques","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.01.001_bib0074","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.001_bib0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0076","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.001_bib0077","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.001_bib0078","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.01.001_bib0079","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.001_bib0080","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"issue":"S2","key":"10.1053\/j.seminhematol.2024.01.001_bib0081","first-page":"141","volume":"39","author":"Wierda","year":"2021","journal-title":"TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO-CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R\/R CLL\/SLL"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.001_bib0082","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2024.01.001_bib0083","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2019-125417","article-title":"Ibrutinib treatment in CLL patients improves T cell function and blinatumomab redirected cytotoxicity","volume":"134","author":"Long","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.01.001_bib0084","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.01.001_bib0086","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3xCD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0087","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/bjh.16300","article-title":"Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study","volume":"189","author":"Thieblemont","year":"2020","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.001_bib0088","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2021-151109","article-title":"Lenalidomide exposure at time of CAR T-cells expansion enhances response of refractory\/relapsed aggressive large B-cell lymphomas","volume":"138","author":"Lemoine","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0089","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.001_bib0090","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/10428194.2022.2043299","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"63","author":"Tettamanti","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.001_bib0091","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Otahal","year":"2016","journal-title":"Oncoimmunology"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2024.01.001_bib0092","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2019-124254","article-title":"Blinatumomab\/lenalidomide in relapsed\/refractory non-Hodgkin's lymphoma: a phase I California Cancer Consortium Study of safety, efficacy and immune correlative analysis","volume":"134","author":"Poh","year":"2019","journal-title":"Blood"},{"issue":"499","key":"10.1053\/j.seminhematol.2024.01.001_bib0093","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.001_bib0094","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omtm.2022.12.002","article-title":"Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors","volume":"28","author":"Braun","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0096","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.01.001_bib0097","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.001_bib0098","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0099","doi-asserted-by":"crossref","unstructured":"Siddiqi T, Abramson JS, Lee HJ, et al. Safety of Lisocabtagene Maraleucel given with durvalumab in patients with relapsed\/refractory aggressive B-cell non Hodgkin lymphoma: first results from the platform study. J Hematol Oncol 2019;37(S2):171-2.","DOI":"10.1002\/hon.128_2629"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.001_bib0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0101","doi-asserted-by":"crossref","unstructured":"Tan Su Yin E, Hu YX, Huang H. The breakthrough and the future: CD20 chimeric antigen receptor T-cell therapy for hematologic malignancies. J Hematol Oncol 2022;2(1):e1039.","DOI":"10.1002\/imed.1039"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.001_bib0102","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ajh.2830400404","article-title":"Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia","volume":"40","author":"Almasri","year":"1992","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.001_bib0103","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.001_bib0104","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.001_bib0106","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.001_bib0107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","article-title":"Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.01.001_bib0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14153618","article-title":"Developing ROR1 targeting CAR-T cells against solid tumors in preclinical studies","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.001_bib0109","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.01.001_bib0110","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.001_bib0111","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1158\/1078-0432.CCR-20-2754","article-title":"CAR T cells targeting human immunoglobulin light chains eradicate mature B-cell malignancies while sparing a subset of normal B cells","volume":"27","author":"Ranganathan","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.01.001_bib0112","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0113","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1078-0432.CCR-17-1193","article-title":"Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug-resistant human B-cell malignancies in vivo","volume":"24","author":"Qin","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12_Supplement","key":"10.1053\/j.seminhematol.2024.01.001_bib0114","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1158\/1538-7445.AM2022-2855","article-title":"Abstract 2855: Antitumor activity of BAFF-R targeting CAR T-cells on chronic lymphocytic leukemia","volume":"82","author":"Luo","year":"2022","journal-title":"Cancer Research"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.001_bib0115","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00262-020-02614-8","article-title":"Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions","volume":"69","author":"Dong","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.001_bib0116","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41375-021-01477-x","article-title":"CD19\/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.001_bib0117","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11523-019-00666-0","article-title":"Plasma B-cell maturation antigen levels are elevated and correlate with disease activity in patients with chronic lymphocytic leukemia","volume":"14","author":"Udd","year":"2019","journal-title":"Target Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.01.001_bib0118","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1053\/j.seminhematol.2024.01.001_bib0119","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0120","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.3389\/fimmu.2020.01965","article-title":"Use of cell and genome modification technologies to generate improved \"Off-the-Shelf\" CAR T and CAR NK cells","volume":"11","author":"Morgan","year":"2020","journal-title":"Front Immunol."},{"issue":"10","key":"10.1053\/j.seminhematol.2024.01.001_bib0121","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.001_bib0122","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.01.001_bib0123","article-title":"Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.001_bib0124","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.01.001_bib0125","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:37:01Z","timestamp":1718411821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":125,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0037196324000039"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}